Using MRI to Study Lung Function in Patients with Pulmonary Fibrosis and Emphysema
Magnetic Resonance Lung Function Imaging Study of Pulmonary Fibrosis Combined With Emphysema Syndrome
This study is testing how MRI scans can help track lung function changes in people with combined pulmonary fibrosis and emphysema over a year to improve early diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 55 (estimated) |
| Sex | All |
| Sponsor | Beijing Chao Yang Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06431555 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize magnetic resonance imaging (MRI) technology to investigate lung function in patients diagnosed with combined pulmonary fibrosis and emphysema syndrome (CPFE). Participants will undergo MRI assessments at baseline, and then again at 6 and 12 months to monitor changes in lung function and correlate these with disease progression. The study focuses on identifying imaging markers that could facilitate early diagnosis of CPFE. By analyzing pulmonary perfusion changes, the research seeks to enhance understanding of this complex condition.
Who should consider this trial
Good fit: Ideal candidates include individuals with imaging-confirmed pulmonary fibrosis and emphysema as described in the eligibility criteria.
Not a fit: Patients who refuse to participate or have contraindications for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management strategies for patients with CPFE.
How similar studies have performed: While the use of MRI in lung function assessment is emerging, this specific approach to studying CPFE is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Chest HRCT shows emphysema mainly distributed in the upper lung field, manifesting as wallless or thin-walled (wall thickness \<1 mm) low-transmittance areas with clear boundaries with normal tissue, or multiple bullae (diameter \> 1 cm), and the emphysema area/total lung volume is ≥10%; (2) interstitial pulmonary fibrosis mainly distributed in the lower lung field and subpleura, manifesting as honeycomb shadow or grid shadow, and the lung structure is destroyed , may be accompanied by traction bronchiectasis, ground glass opacities and consolidation opacities. Exclusion Criteria: * (1) Refusal to sign the informed consent form; (2) MRI contraindications (implanted pacemaker/defibrillator, claustrophobia, or any clinical condition that prohibits longer MRI examinations).
Where this trial is running
Beijing, Beijing
- Beijing Chaoyang Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Tao Ouyang, PhD
- Email: ouyt1996@163.com
- Phone: +86 18720931226
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.